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The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the
development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in
colorectal cancer in 1986, over 80 different fusion partner genes have been identified in a wide array of adult and paediatric
tumours, providing actionable targets for targeted therapy. This review describes the normal function and physiology of TRK
receptors and the biology behind NTRK gene fusions and how they act as oncogenic drivers in cancer. Finally, an overview of
the incidence and prevalence of NTRK gene fusions in various types of cancers is discussed.
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Introduction
The identification of gene fusions in a variety of cancers has pro-
vided actionable targets that have expanded therapeutic options
and facilitated precision medicine. These gene aberrations result
in the expression of fusion proteins with constitutive activity that
become oncogenic drivers [1]. The tropomyosin receptor kinase
(TRK) family of receptor tyrosine kinases are of interest as the
NTRK genes that encode them are involved in gene fusions iden-
tified in a wide range of adult and paediatric tumours.
In this review, we discuss the normal function and physiology
of TRK receptors, the biology behind NTRK gene fusions, the
mechanisms by which NTRK gene fusions become oncogenic
drivers in cancer, and the incidence and prevalence of NTRK
gene fusions in a variety of cancers.
Normal function and physiology of NTRK genes
and TRK receptors
Structure. TRKA, TRKB and TRKC are transmembrane proteins
that comprise the TRK receptor family. TRKA is encoded by the
NTRK1 gene located on chromosome 1q21-q22 [2]. TRKB is
encoded by the NTRK2 gene located on chromosome 9q22.1 [3].
TRKC is encoded by the NTRK3 gene located on chromosome
15q25 [4]. Each of the TRK receptors consists of an extracellular
domain, a transmembrane region and an intracellular region
containing the tyrosine kinase domain. The extracellular domain
contains a cysteine-rich cluster (C1) followed by three leucine-
rich 24-residue repeats (LRR1–3), another cysteine-rich cluster
(C2) and two immunoglobulin-like domains (Ig1 and Ig2;
Figure 1) [5–7]. The LRR1–3 motifs are specific to TRK proteins
and are not found in other receptor tyrosine kinases [6]. The
intracellular region contains five key tyrosine residues (Figure 1):
three within the activation loop of the kinase domain, which are
necessary for full kinase activity, and two on either side of the
tyrosine kinase domain, which serve as phosphorylation-
dependent docking sites for cytoplasmic adaptors and
enzymes [8].
TRK receptors and associated ligands. The TRK receptors are
activated by a family of four proteins called neurotrophins.
Neurotrophins were initially identified as survival molecules for
sensory and sympathetic neurons [9], but are now understood to
play many roles in the development and function of the nervous
system [10]. Each of the four neurotrophins have specificity for a
particular TRK and bind to it with high affinity (Figure 1). Nerve
growth factor (NGF) binds to TRKA [11, 12], both brain-derived
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neurotrophic factor (BDNF) and neurotrophin 4 (NT-4) bind to
TRKB [13–15] and neurotrophin 3 (NT-3) binds to TRKC [16].
NT-3 can bind to all three TRK receptors but has highest affinity
for TRKC and is its sole ligand [14, 15, 17, 18]. Alternative splic-
ing of TRK proteins can alter the interaction between a TRK re-
ceptor and its specific neurotrophin (Figure 2) [10, 19]. For
example, short amino acid sequence insertions observed in the
juxtamembrane region of the extracellular domains of TRKA and
TRKB enhance their binding with non-cognate ligands [20, 21].
Isoforms of TRKA and TRKB that lack this insertion are activated
strongly only by NGF and BDNF, respectively. In contrast, with
this insertion, the TRKA splice variant is activated by NT-3 in
addition to NGF [20] and the TRKB splice variant is readily acti-
vated by NT-3 and NT-4 in addition to BDNF [21]. Alternative
splicing of exons encoding parts of the intracellular domains of
TRK receptors may also affect downstream signalling initiated by
neurotrophin binding to the receptor. Such alternatively spliced
TRKB and TRKC isoforms have been observed to contain com-
paratively short cytoplasmic motifs missing the tyrosine kinase
domain, leading to a lack of receptor response to neurotrophins
[22]. For example, alternative splicing of the NTRK3 gene may
lead to amino acid insertion into the TRKC tyrosine kinase do-
main, which in turn results in modified kinase substrate
specificity and impaired ability to promote neuronal cell differen-
tiation [23].
Normal TRK signalling pathway. The TRK signalling pathway is
initiated when neurotrophin binding to TRK receptors at the cell
surface causes the formation of receptor dimers (Figure 3A). The
dimerised receptor autophosphorylates specific tyrosine residues
in the activation loop of the kinase domain [Y676, Y680 and
Y681 in TRKA (Figure 3B) and the corresponding residues in
TRKB and TRKC] [8]. This phosphorylation is required for acti-
vation of the TRK receptor [6] and leads to subsequent
phosphorylation of additional tyrosine residues (Y496 and Y791
in TRKA), enabling docking of cytoplasmic adaptors and
enzymes [5–7], which in turn drives a variety of downstream
signalling pathways [6]. The binding of TRKA by NGF causes
activation of the RAS/MAPK pathway, leading to increased
cellular proliferation and growth via ERK signalling [24, 25].
Neurotrophic binding to TRKB results in activation of the
RAS-ERK, PI3K and PLCc pathway, resulting in neuronal differ-
entiation and survival [24, 25]. TRKC binding to NT-3 causes
preferential activation of the PI3K/AKT pathway, preventing
apoptosis and increasing cell survival [24, 25].
Role in development and physiology. TRK receptors are predom-
inantly expressed in neuronal tissue and play an essential role
during embryonic development as well as in the normal function
of the nervous system [7, 26]. The activation of TRK receptors by
neurotrophins has an impact on a variety of neuronal events,
such as neuronal cell differentiation and survival, cell prolifer-
ation, synaptic formation and plasticity, membrane trafficking,
and axon and dendrite formation [7, 19, 27].
TRK receptors and their respective neurotrophins have been
implicated in the survival and differentiation of sensory ganglia.
TRKA receptors are expressed in almost all nociceptive neurons
in the dorsal root and trigeminal ganglia [28, 29], while dorsal
root ganglia neurons that differentiate in proprioceptive neurons
start expressing TRKC during neurogenesis. Neurons in the
nodose-petrosal ganglion, which conveys visceral sensory infor-
mation about blood pH and pressure, express TRKB and are de-
pendent on BDNF for development and differentiation [30, 31].
TRK receptors and their respective neurotrophins have been
implicated in memory formation and retention, nociception and
proprioception [31, 32], as well as having roles in non-neuronal
tissues including the vasculature, ovaries and immune system
[33–36]. Loss-of-function mutations inNTRK genes can result in
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Figure 1. Structure of TRK receptors and interaction with ligands [5]. The neurotrophins display specific interactions with the three TRK
receptors: NGF binds TRKA, BDNF and NT-4 bind TRKB and NT-3 binds TRKC. NT-3 can also activate TRKA and TRKB albeit with less efficiency.
BDNF, brain-derived neurotrophic factor; C1/C2, cysteine-rich clusters; Ig1/Ig2, immunoglobulin-like domains; LRR1–3, leucine-rich repeats;
NGF, nerve growth factor; NT-3/4, neurotrophin 3/4; TRK, tropomyosin receptor kinase.
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several diseases, indicating the role of TRK receptors in normal
regulation and function. TRKA receptors are involved in pain
sensation; loss-of-function mutations in TRKA are observed in
class IV hereditary sensory and autonomic neuronal disorders
(such as congenital insensitivity to pain with anhidrosis), which
result in impaired ability to sense differences in temperature or
feel pain [37, 38]. Loss-of-function mutations in TRKB result in
energy imbalances, loss of appetite control and subsequent obes-
ity, in addition to defects in learning, memory and nociception
[39–41].
Discovery of aberrant gene fusions and ligand-
independent oncogenic proteins
Discovery of NTRK gene fusions in cancer. Somatic fusions
involving the NTRK genes were first observed in a patient with
colorectal cancer (CRC) in 1986, when Martin-Zanca et al. iden-
tified a chimeric fusion oncogene resulting from an intrachromo-
somal rearrangement at 1q22-23 [42]. This oncogene involved
the tropomyosin 3 gene (TPM3) and a locus that was subsequent-
ly cloned and found to encode a high-affinity NGF receptor
(NTRK1) [12]. Following the discovery of this TPM3-NTRK1
gene fusion, the identification of other NTRK gene fusions in
CRC [43–45] triggered the interest of clinicians in the possible ex-
istence of oncogenic gene fusions in other types of cancers; to
date, over 80 different fusion partner genes have been identified
in a wide array of tumours (Figure 4).
Oncogenic mechanism of NTRK gene fusions. In NTRK gene fu-
sion events, the 30 region of the NTRK gene is joined with the 50
end of a fusion partner gene, either by intrachromosomal or
interchromosomal rearrangement. The resulting fusion gene enc-
odes a protein containing the N-terminus of the fusion partner
joined to the C-terminus of the TRK protein, including the
catalytic tyrosine kinase domain [27]. The majority of character-
ised NTRK gene fusions contain a 50 partner gene sequence
encoding one ormore dimerisation domains. These domains me-
diate the corresponding constitutive tyrosine kinase activity that
occurs, thus conferring ligand-independent oncogenic potential
through uninterrupted downstream signalling messages, pro-
moting cell proliferation and survival [27].
Incidence and prevalence of NTRK gene fusions
Incidence and prevalence data for NTRK gene fusions have only
recently become clearer following the increasing availability of
next-generation sequencing (NGS) and comprehensive molecu-
lar testing methods. NTRK gene fusions have been identified in
two main categories of tumours with vastly differing rates of oc-
currence; certain rare cancers present with a high frequency
(>80%) of NTRK gene fusions, while some more common can-
cers present with a lower frequency of NTRK gene fusions
(<25%) [24, 27, 46]. NTRK gene fusions have been estimated to
occur in up to 1% of all solid tumours [27, 46, 47]. Gene fusion
events appear to arise more commonly in the NTRK1 and
NTRK3 genes, with the possible exception of brain tumours [27,
46–48]. Immunohistochemistry (IHC) screening in 1043 various
solid tumours showed TRKA expression in 1.6% of samples,
including CRC, lung cancer, biliary tract carcinoma and thyroid
cancer. Of note, only 5.9% of these showed NTRK gene rear-
rangements, while 88.2% of cases displayed NTRK1 gene copy
number gain without amplification [49]. In a retrospective ana-
lysis of 33 997 patients, screening with a targeted DNA-based
NGS panel (MSK-IMPACT) identified 87 patients (0.26%) with
oncogenic NTRK1–3 gene fusions. The prevalence of NTRK1–3
gene fusions in this group ranged from 0.13% to 17.7% depend-
ing on the various tumour types. Screening with pan-TRK IHC in
this study showed better sensitivity than DNA-based NGS
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Figure 2. Known splice variants of TRKA, TRKB and TRKC [6]. C1/C2, cysteine-rich clusters; Ig1/Ig2, immunoglobulin-like domains; KD, kinase
domain; LRR1–3, leucine-rich repeats; TM, transmembrane; TRK, tropomyosin receptor kinase.
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(87.9% versus 81.1%) but reduced specificity (81.1% versus
99.9%) [50].
NTRK gene fusions are pathognomonic in certain rare paediatric
and adult cancers. Infantile fibrosarcoma (IFS), a malignant tu-
mour of fibroblasts, represents <1% of all paediatric cancers but
is the most commonly occurring non-rhabdomyosarcoma soft
tissue sarcoma in children under 1 year of age [47]. IFS is virtually
identical histologically to the cellular variant of congenital meso-
blastic nephroma (CMN), an infantile spindle cell tumour of the
kidney that occurs in the same age group and represents 5% of
all childhood renal neoplasms. In 1998, Knezevich et al. discov-
ered a recurrent ETV6-NTRK3 gene fusion in IFS, which was
found to occur in 70% of cases of IFS [51]. The same year, two
other groups identified the same ETV6-NTRK3 gene fusion in the
cellular variant of CMN, establishing a genetic link between IFS
and cellular CMN [52, 53]. Thereafter, identification of the
ETV6-NTRK3 translocation has become a useful diagnostic
marker for IFS/CMN, and the presence of this gene fusion is con-
sidered pathognomonic for these two rare cancers. Several add-
itional novel translocations involving NTRK genes have
subsequently been described in IFS/CMN [54, 55] (Figure 4);
consequently, genomic testing using break-apart fluorescence in
situ hybridisation specific for ETV6may be insufficient both as a
diagnostic and predictive marker [56].
Secretory breast carcinoma (SBC) is one of the rarest types of
breast carcinomas, accounting for 0.15% of all breast cancers
[57]. It is characterised by intracellular and extracellular eosino-
philic secretions and usually presents as a triple-negative breast
carcinoma with an immunohistochemical profile akin to basal-
like breast carcinoma. Tognon et al. first reported an ETV6-
NTRK3 gene fusion in 12 out of the 13 cases of SBC by identifying
the corresponding chromosomal translocation t(12; 15)(p13;
q25) [58].
Mammary analogue secretory carcinoma (MASC) is a rare
neoplasm of minor and major salivary glands morphologically
and immunohistochemically similar to SBC. Since it was first
described in 2010 by Ska´lova´ et al. [59], fewer than 300 cases have
been reported in the literature [60]. Ska´lova´ et al. found that of 14
cases of MASC, all but one was characterised by the ETV6-
NTRK3 gene fusion [59]. While ETV6-NTRK3 is the most com-
mon gene fusion seen in MASC, other rearrangements involving
ETV6 and NTRK1 or NTRK2 have been identified [53]. On the
other hand, no partner genes other than ETV6 have been
described in cases of MASC harbouring NTRK3 rearrangement
(Figure 4).
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Figure 3. TRK signalling pathway. (A) Overview of TRK signalling pathway; (B) activation of TRKA. C1/C2, cysteine-rich clusters; Ig1/Ig2,
immunoglobulin-like domains; LRR1–3, leucine-rich repeats; NGF, nerve growth factor; TRK, tropomyosin receptor kinase, TRKi, tropomyosin
receptor kinase inhibitor.
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NTRK gene fusions in common cancers. Thyroid cancer:
Papillary thyroid carcinoma (PTC) is the most common type of
thyroid cancer, accounting for 80% of all thyroid cancer cases
[61]. Since the identification of NTRK1 as an oncogenic driver in
PTC by Bongarzone et al. in 1989 [62], the reported frequency of
NTRK1 rearrangement in PTC has been shown to range from
<5% to 25% [63–68]. More recently, novel NTRK3 fusion genes
have been discovered in PTC, with ETV6-NTRK3 being the most
common rearrangement found after any RET-PTC isoform in
The Cancer Genome Atlas Project [61]. While the prevalence of
ETV6-NTRK3 in PTC in adults is very low (1%), it is the second
most common rearrangement seen in radiation-associated PTC
[69, 70].
Colorectal and appendiceal cancer: Following the identifica-
tion of TPM3-NTRK1 as an oncogenic driver in CRC in 1986
[42], the third most common form of cancer, nothing further
was reported about this gene fusion until almost 30 years later
when Ardini et al. characterised the TPM3-NTRK1 rearrange-
ment at the genomic level for the first time, finding that the
observed breakpoint within exon 8 of NTRK1 in CRC differed
from those previously identified for the TPM3-NTRK1 gene fu-
sion in PTC. This group also developed and validated an IHC
method for the identification of TRKA-positive clinical speci-
mens, offering a readily applicable approach to screening CRC
for TRKA overexpression and thus identifying those cases that
could potentially benefit from targeted therapy [43]. Further
cases of CRC harbouring either NTRK1 or NTRK3 gene fusions
involving different partner genes have subsequently been
reported and, in some cases, demonstrated pharmacologically ac-
tionable (Figure 4) [44, 45, 71–73]. A recent molecular profiling
study used a plasma-based cell-free circulating tumour DNA
NGS assay to detect gene fusions in 4290 patients with CRC.
Using different gene panels, including one testing for NTRK1
(but not NTRK2 or NTRK3) gene fusions, only three (0.07%)
cases were detected [74]. These data are consistent with the preva-
lence previously found using a tissue-based NGS assay [75].
Notably, gene fusions seem to be associated with high mutation
burden [74], and microsatellite instability (MSI) is frequently
found in CRCs harbouring NTRK gene fusions [44, 71, 76].
Hypothetically, the increased mutational frequency in MSI-high
CRCs could explain the higher incidence of NTRK gene rear-
rangements as well as NTRK mutations [77]. To date, only
NTRK2 fusions have been identified in cases of appendiceal
adenocarcinoma [73, 78].
Lung cancer: Lung cancer is the leading cause of cancer-related
mortality in the world. Non-small-cell lung cancer (NSCLC) is
the most common type of lung cancer, accounting for 85% of all
lung cancer cases [79]. NTRK1 gene rearrangements in NSCLC
were first described in 2013 among a subset of patients with
NSCLC with adenocarcinoma histology and no detectable EGFR,
KRAS, ALK or ROS1 alterations (3/91; 3.3%) [80]. In a larger and
unselected cohort of 1378 patients with NSCLC, NTRK1 gene
fusions were detected in two patients (0.1%) [81]. NTRK2 and
NTRK3 gene fusions in NSCLC have also been described [48, 82].
Overall, NTRK gene fusions occur at a frequency of
0.1%1.0% [27, 80, 81] (Figure 4).
Sarcoma: NTRK gene fusions are relatively rare in soft tissue
sarcoma. Testing on 1272 soft tissue sarcoma samples identified
eight cases (<1%) with NTRK1 or NTRK3 gene fusions, with
one-half of these found in patients under the age of 5 years [83].
RecurrentNTRK1 gene fusions have been noted in soft tissue sar-
comas characterised by a prominent myopericytic/haemangio-
pericytic growth pattern [84]. Several studies involving the
genetic sequencing of tumour samples have led to the character-
isation of novel subtypes of sarcoma not previously described.
Undifferentiated uterine sarcoma is a diagnosis of exclusion after
more common uterine mesenchymal tumours, such as leiomyo-
sarcoma, have been ruled out. From a database of gynaecological
cancer patients, Chiang et al. prospectively identified four NTRK
gene fusion-positive undifferentiated uterine sarcomas with
spindle cell morphology that were morphologically and immu-
nophenotypically unique from leiomyosarcoma and other undif-
ferentiated uterine sarcoma. This discovery suggested a novel
uterine sarcoma subtype defined by the presence of recurrent
NTRK gene fusions [85]. Similarly, Agaram et al. described a
novel and distinct subset of NTRK1 gene fusion-positive soft tis-
sue tumours occurring in children and young adults resembling
lipofibromatosis (LPF) but displaying cytologic atypia and a
neural immunophenotype. These tumours have been provision-
ally named LPF-like neural tumours and are defined by NTRK1
oncogenic activation [86]. ETV6-NTRK3 gene fusions have also
been identified in inflammatory myofibroblastic tumours in ado-
lescent and adult patients [87], especially in ALK-negative
tumours [88, 89].
Central nervous system cancers: NTRK gene fusions have been
identified in both paediatric and adult primary central nervous
system (CNS) tumours, including glioblastoma multiforme
(GBM), paediatric gliomas and astrocytomas [27]. Frattini et al.
analysed 185 samples of GBM and discovered 2 NTRK1 gene
fusions (1%) with two different 50 fusion partners (NFASC-
NTRK1 and BCAN-NTRK1) [90]. Several additional NTRK
translocations have subsequently been described in GBM
(Figure 4). In a series of 127 paediatric high-grade gliomas
(HGGs), Wu et al. reported recurrent fusions involving NTRK
genes in 4% of diffuse intrinsic pontine gliomas and 10% of non-
brainstem HGGs (NBS-HGGs). Notably, 40% (4/10) of NBS-
HGGs in children aged<3 years harboured anNTRK gene fusion
[91]. Different fusions involving NTRK genes have also been
reported in low-grade gliomas (Figure 2). Low-grade neuroepi-
thelial tumours (LGNTs) are a diverse group of CNS tumours
presenting in children and young adults; pilocytic astrocytomas
are the most common LGNT seen in children. Jones et al. used
whole-genome sequencing to analyse 96 pilocytic astrocytomas
and identified two novel NTRK2 gene fusions (QKI-NTRK2 and
NACC2-NTRK2) in three samples [92]. Qaddoumi et al. also uti-
lised whole-genome sequencing to analyse 91 less common
LGNTs and identified two tumours harbouring NTRK2 translo-
cations, including a novel SLMAP-NTRK2 gene fusion found in a
case of parietal ganglioglioma [93]. NTRK rearrangements have
also been reported in diffuse leptomeningeal glioneuronal
tumours [94]; rare CNS neoplasms that were included in the
2016 update of the World Health Organization classification
[95]. In addition, cancers that can harbour NTRK gene fusions,
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such as lung cancers and melanomas, have a proclivity for CNS
metastases [27, 96].
Spitzoid tumours/melanoma: Various translocations involving
NTRK1 or NTRK3 have been reported in spitzoid melanocytic
neoplasms as well as in compound Spitz nevi [97–99]. More re-
cently, an NGS analysis was carried out by Lezcano et al. in order
to assess the frequency of NTRK gene rearrangements in non-
spitzoid metastatic melanomas. Among 751 cases, they identified
three cutaneous primary melanomas (3/395; 0.8%) and one mu-
cosal/paramucosal melanoma (1/113; 0.9%) harbouring NTRK1
orNTRK2 gene fusions [100].
Other tumour types: TRK fusions have also been reported in
intrahepatic cholangiocarcinomas [101], breast cancer [102],
quadruple wild-type (ETV6-NTRK3) gastrointestinal stromal
tumours [103, 104], gallbladder adenocarcinomas [73], pancreat-
ic carcinomas [105], sinus-nasal low-grade non-intestinal-type
adenocarcinomas [106] and neuroendocrine tumours of the
small bowel [107]. In addition to being present in solid tumours,
NTRK gene fusions are also detected in acute lymphoblastic leu-
kaemia (ALL) [108] and acute myeloid leukaemia [109] at a fre-
quency of<5% [6].
Preclinical and clinical evidence that NTRK gene
fusions are oncogenic drivers
Preclinical studies with inhibitors of TRK proteins have further
substantiated the role ofNTRK gene fusions as oncogenic drivers.
Mouse models of genetically engineered NTRK gene fusion-
positive cancers have been shown to develop highly aggressive
tumours. Two such studies involved a conditional knock-in
model of carrying the Etv6-NTRK3 gene fusion [109] and a
chromosomal engineered glioma model harbouring the Bcan-
Ntrk1 gene fusion [110]. In bothmodels, the tumours were effect-
ively controlled using TRK inhibitors, indicating that the TRK fu-
sion protein was implicated in the proliferation and survival of
tumour cells. In a separate in vitro study, analysis of CRC cell lines
revealed NTRK1 overexpression that was associated with gene
translocation. When this gene was suppressed through the use of
short interfering RNA or TRKA inhibition, the ensuing reduction
in protein expression or activity significantly impaired cell
growth and increased apoptosis, suggesting functional depend-
ency [111]. Furthermore, studies in mice demonstrated that con-
ditional expression of an Etv6-NTRK3 gene fusion was sufficient
to initiate mammary tumourigenesis [112]. Importantly, NTRK
gene fusions appear to be mutually exclusive to other gene altera-
tions, suggesting that they may act as the sole oncogenic drivers
in the tumours that harbour them [48, 82, 113].
Additional preclinical and clinical studies of tyrosine kinase
inhibitors have provided further evidence of NTRK gene fusions
as oncogenic drivers. Entrectinib (RDX-101, NMS-P626), a mul-
tikinase inhibitor, was shown to suppress TPM3-TRKA protein
phosphorylation in mice with CRC harbouring a TPM3-NTRK1
gene fusion [43], and further showed efficacy in three clinical tri-
als including patients with NTRK gene fusions [114, 115].
Larotrectinib is a highly selective TRK inhibitor recently
approved by the US Food and Drug Administration* for the
treatment of adult and paediatric patients with solid tumours
that harbour an NTRK gene fusion. Larotrectinib inhibited fu-
sion protein signalling, in vitro proliferation and in vivo tumour
growth in models derived from human cancer cells harbouring
NTRK gene fusions [80, 97], as well as demonstrated clinical effi-
cacy and safety in three clinical trials [46, 116, 117]. Resistance to
larotrectinib and entrectinib can occur through the development
of NTRK gene mutations, which involves amino acid substitu-
tions in the solvent-front, gatekeeper residues of the NTRK genes
(NTRK1 p. G667C, NTRK3 p. G696A) and xDFG motif substitu-
tions [114, 118]. Second-generation TRK inhibitors, such as
selitrectinib (BAY 2731954, LOXO-195), are under clinical devel-
opment based on their ability to overcome acquired resistance
mediated by these acquired recurrent mutations [114].
Other NTRK alterations, such as mutations, amplifications
and mRNA overexpression, were found in 14% of 13 467 adult
and paediatric pan-cancer tumour samples obtained from The
Cancer Genome Atlas and the St Jude PeCan database [119].
NTRK mutations occur less frequently than amplifications or
mRNA overexpression [119], but may be enriched in MSI-high
CRCs [77]. These NTRK mutations are different from the
acquired mutations described as a resistance mechanism to TRK
inhibitors; as expected, the known acquired NTRK mutations
that confer resistance were not observed in any of the 13 467
treatment-naı¨ve tumours [119]. NTRK point mutations them-
selves are generally not activating oncogenic events [120] and
have limited response to larotrectinib, as demonstrated in a phase
I clinical trial of larotrectinib [117] where none of the patients
with NTRK point mutations had an objective response to laro-
trectinib; in contrast, objective responses were seen in seven of
eight patients with tumours harbouring NTRK gene fusions. The
oncogenic role of TRK overexpression andNTRK gene amplifica-
tion also remains unclear [6]. In the same trial with larotrectinib,
one patient with a tumour harbouring anNTRK1 gene amplifica-
tion had a single 11mm target lesion shrink by 5mm (45.5%).
The duration of response for this patient was 3.7months, whereas
in the patients with TRK fusion cancer the median duration of re-
sponse had not been reached at a median follow-up of
26.9months [117].
Lessons learned
NTRK gene fusions can be drivers of cancer progression and, as
such, their oncogenic products can be therapeutically targeted.
Specific NTRK gene fusions have been identified in various
tumours and can be found with high prevalence in certain rare
adult and paediatric tumour types, even becoming a defining
diagnostic feature, and at low prevalence in most common can-
cers. Advances in both NTRK gene fusion detection and targeted
therapies to inhibit TRK are changing the diagnostic and thera-
peutic landscape of treatment of these cancers [46, 96].
*Note added in proof: The European Medicines Agency granted marketing authorisation for larotrectinib on 23 September 2019 as monotherapy for the treatment of adult and
paediatric patients with solid tumours that display a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and who have disease that is locally advanced, metastatic or
where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.
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